Sengenics seeing 'explosive growth' in partnerships with 9/10 top pharma companies
Sorry, only registred users can create playlists.
Description
Sengenics Corporation Pte Ltd Global Business Unit Director Andrew Jackson sat down with Proactive’s Christine Corrado at the BIO CEO & Investor Conference in New York.
The Singapore-based company's KREX technology is being developed to discover autoantibody biomarkers to predict drug response and severe immune-related adverse events.
Comments